title: Achieving translation in models of visceral pain.
abstract: The failure of drugs to modify pain end points in clinical trials for irritable bowel syndrome (IBS) highlights the knowledge gap that exists in the translation of efficacy in animal models of visceral pain into the clinic. Recent progress has been made towards improving the translation of visceral pain, particularly with regard to the activation of the sensory nerves which relay pain from the gut to the brain. This review will focus on studies which have identified the presence of an altered gastrointestinal and immune environment in IBS patients. The development of human gastrointestinal visceral afferent recordings has allowed direct comparison between sensory nerve studies in animals and human, as well as important advances in our understanding of the ion channels that underpin the changes in sensory nerve excitability.
authors: Wingate Institute of Neurogastroenterology, Blizard Institute, Bart's and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AJ, United Kingdom. d.bulmer@qmul.ac.uk
authors: David Colin
authors: DC
authors: Bulmer
authors: David
authors: D
authors: Grundy
mesh_terms: D015746:Abdominal Pain / Q000188:drug therapy* / Q000209:etiology; D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D004195:Disease Models, Animal; D005765:Gastrointestinal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D041981:Gastrointestinal Tract / Q000187:drug effects / Q000294:innervation* / Q000378:metabolism; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D058990:Molecular Targeted Therapy; D010147:Pain Measurement / Q000379:methods; D026902:Potassium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D015221:Potassium Channels / Q000378:metabolism; D011984:Sensory Receptor Cells / Q000187:drug effects / Q000378:metabolism; D026941:Sodium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D015222:Sodium Channels / Q000378:metabolism; D050051:Transient Receptor Potential Channels / Q000037:antagonists & inhibitors / Q000378:metabolism; D057170:Translational Research, Biomedical
chemical_list: D000700:Analgesics; D005765:Gastrointestinal Agents; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D026941:Sodium Channel Blockers; D015222:Sodium Channels; D050051:Transient Receptor Potential Channels